companiesCompany
Aadi Bioscience
aka Whitehawk Therapeutics, Aadi Bioscience, Inc., NASDAQ:AADI
Aadi Bioscience won approval for Fyarro, the albumin-bound sirolimus that treats the rare sarcoma PEComa, then sold it and renamed itself Whitehawk Therapeutics to develop antibody-drug conjugates.
Overview
Aadi Bioscience developed nab-sirolimus (Fyarro, ABI-009), an mTOR inhibitor bound to albumin nanoparticles for better tumour delivery. The FDA approved it in November 2021 for malignant perivascular epithelioid cell tumour, the first drug for that sarcoma; the PRECISION 1 trial tested it in tumours with TSC1 or TSC2 alterations. In 2025 Aadi sold Fyarro to Kaken Pharmaceutical, in-licensed three antibody-drug conjugates from WuXi Biologics and Hangzhou DAC, and became Whitehawk Therapeutics.
Headquarters
Los Angeles, California, US
Scorecard
All companies#270of 1181 companies, score 13
- approved products +6
- targets +2
- modalities +2
- regions +1
- registry trials +2
1 approved, 0 in phase 3, 0 earlier, 1 targets, 1 registry studies. Formula on the scorecards page.
Type
biotech · NASDAQ:AADI
Stage
Public
Website